Accelerated approval mandates ctDNA-confirmed ESR1 mutation emergence during ongoing AI+CDK4/6 therapy, prompting AI replacement with camizestrant while maintaining abemaciclib, palbociclib, or ...
WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has approved the country’s first mRNA-based influenza vaccine, developed by Moderna. The vaccine is approved for adults aged 50 to 64 and ...